Biosimilars: To switch or not to switch – that is the question
More details
Hide details
Division of Rheumatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
Online publication date: 2020-02-28
Reumatologia 2020;58(1):1-3
Wilson AW, Neumann PJ. The cost-effectiveness of biopharmaceuticals: a look at the evidence. MAbs 2012; 4: 281-288, DOI: 10.4161/mabs.4.2.18812.
Castañeda-Hernández G, Szekanecz Z, Mysler E, et al. Biopharmaceuticals for rheumatic diseases in Latin America, Europe, Russia, and India: innovators, biosimilars, and intended copies. Joint Bone Spine 2014; 81: 471-477, DOI: 10.1016/j.jbspin.2014.03.019.
Sarzi-Puttini P, Marotto D, Caporali R, et al. Biosimilars vs originators: Are they the same? Autoimmun Rev 2019; 18: 102404, DOI: 10.1016/j.autrev.2019.102404.
Pentek M, Zrubka Z, Gulacsi L. The Economic Impact of Biosimilars on Chronic Immune-Mediated Inflammatory Diseases. Curr Pharm Des 2017; 23: 6770-6778, DOI: 10.2174/1381612824666171129193708.
Vulto AG, Jaquez OA. The process defines the product: what really matters in biosimilar design and production? Rheumatology (Oxford) 2017; 56 (Suppl 4): iv14-iv29, DOI: 10.1093/rheumatology/kex278.
Griffiths CEM, Thaci D, Gerdes S, et al. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol 2017; 176: 928-938, DOI: 10.1111/bjd.15152.
Kawalec P, Stawowczyk E, Tesar T, et al. Pricing and reimbursement of biosimilars in Central and Eastern European countries. Front Pharmacol 2017; 8: 288, DOI: 10.3389/fphar.2017.00288.
Solau-Gervais E, Laxenaire N, Cortet B, et al. Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody. Rheumatology (Oxford) 2006; 45: 1121-1124.
Brodszky V, Bíró A, Szekanecz Z, et al. Determinants of biological drug survival in rheumatoid arthritis: evidence from a Hungarian rheumatology center over 8 years of retrospective data. Clinicoecon Outcomes Res 2017; 9: 139-147, DOI: 10.2147/CEOR.S124381.
Goll GL, Jorgensen KK, Sexton J, et al. Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial. J Intern Med 2019; 285: 653-669, DOI: 10.1111/joim.12880.
Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017; 76: 960-977, DOI: 10.1136/annrheumdis-2016-210715.
Hodinka L, Bálint P, Bender T, et al. Treatment of arthritides with synthetic and biologic antirheumatic drugs [Hungarian]. Immunology Quarterly (Budapest) 2015; 7: 4-25.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Journals System - logo
Scroll to top